Ask AI
ProCE Banner Activity

Newly Diagnosed HER2-Positive Metastatic Breast Cancer: Treatment Options and Key Considerations

PDF

Infographic resources with patients thoughts on their care for newly-diagnosed HER2-positive breast cancer with findings and perspectives from a SmartPatients™ focus group. 

Released: May 20, 2025

Expiration: November 20, 2026

Share

Provided by

Provided by Clinical Care Options, LLC. in partnership with Smart Patients

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Aditya Bardia, MD, MPH, FASCO: consultant/advisor/speaker: Alyssum, Daiichi Sankyo/AstraZeneca, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, Pfizer, Sanofi; researcher: Daiichi Sankyo/AstraZeneca, Genentech, Gilead, Lilly, Menarini, Merck, Novartis, Pfizer, Sanofi.

Adrienne G. Waks, MD: researcher (paid to institution): Genentech, Gilead, MacroGenics, Merck; consultant/advisor/speaker: Ambrx, AstraZeneca.